4 BioPharm International
®
Next-Generation Biotherapeutics April 2025 www.biopharminternational.com
Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_
KENTOH
-
STOCK.ADOBE.COM
T
he biopharmaceutical R&D landscape has
undergone signicant transformation in the
past decade, as evidenced by unprecedented
diversity in the industry's pipeline compo-
sition as well as current therapeutic approaches.
In today's biopharma R&D environment, there is
a critical shift from traditional primary-care focus
to a more nuanced, specialty-driven landscape.
Pipeline composition and modality evolution
Today's biopha rmaceut ica l pipeline represents a
complex, multifaceted approach to therapeutic de-
velopment, notes Kevin Dondarski, principal, Life
Sciences R&D, at Deloitte Consulting. He obser ves
that, where previous generations concentrated on
narrow therapeutic domains, current research spans
a broad spectrum of modalities and mechanisms of
action. "If I think about where we are today, there is
such a diverse blend of different modalities, but also
mechanisms of action, that are in the holistic indus-
tr y pipeline. Simply from an oncology standpoint,
[for example], we've seen a proliferation of antibody
drug conjugates [ADCs]," Dondarski remarks.
He emphasizes that, in oncology alone, the indus-
try is witnessing widespread innovation, not only in
ADCs, but also in next-generation programmed cell
death protein 1 (PD-1)/programmed cell death ligand
1 (PD-L1) inhibitors, Bruton's tyrosine kinase (BTK)
inhibitors, and Kirsten rat sarcoma viral oncogene
homolog G12C mutation (KRAS G12) inhibitors. In
addition, Dondarski explains, immunology research
has expanded dramatically, with research investi-
gations intensively targeting multiple interleukin
(IL) pathways, including IL-5, IL-6, IL-13, and IL-17.
Feliza Mirasol
Emerging Modalities and
Strategic Innovation in the
Biopharma R&D Landscape
The biopharmaceutical landscape is undergoing a huge shift
from traditional therapies to more specialty-driven modalities.
